annual meeting program - American Society of Clinical Oncology

1:15 PM - 2:45 PM
CLINICAL SCIENCE SYMPOSIUM
Saturday, June 5, 2010
Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and Quality
of Life
Location: N Hall B1
CME credit: 1.5
Track(s): Gastrointestinal (Noncolorectal) Cancer
David Linehan, MD—Co-Chair
Washington University School of Medicine
Colin D. Weekes, MD, PhD—Co-Chair
University of Colorado Cancer Center
1:15 PM Updated safety and efficacy results of the phase III trial of sunitinib (SU)
versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors
(NET). (Abstract #4000)
P. Niccoli, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas, J. W. Valle, S. Patyna,
D. Lu, R. C. Chao, E. Raymond
1:30 PM A prospective, multi-institutional phase II study of GW786034 (pazopanib)
and depot octreotide (sandostatin LAR) in advanced low-grade
neuroendocrine carcinoma (LGNEC). (Abstract #4001)
A. T. Phan, J. C. Yao, D. R. Fogelman, K. R. Hess, C. S. Ng, S. A. Bullock,
P. Malinowski, E. Regan, M. Kulke
1:45 PM Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to
intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as
functional biomarker. (Abstract #4002)
J. C. Yao, A. T. Phan, D. Fogleman, C. S. Ng, C. B. Jacobs, C. D. Dagohoy,
C. Leary, K. R. Hess
Discussion
2:00 PM Kjell E. Oberg, MD, PhD (Abstracts #4000–4002)
Uppsala University
2:15 PM Patient-reported outcomes (PROs) in patients (pts) with pancreatic
neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial.
(Abstract #4003)
A. Vinik, Y. Bang, J. Raoul, J. W. Valle, P. Metrakos, D. Hörsch, B. Korytowsky,
R. Mundayat, R. C. Chao, E. Raymond
Discussion
2:30 PM Ian Chau, MD (Abstract #4003)
Royal Marsden Hospital
139
SATURDAY